Doris Benbrook to Aged
This is a "connection" page, showing publications Doris Benbrook has written about Aged.
Connection Strength
0.417
-
Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018 06; 40(3):325-336.
Score: 0.077
-
Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64.
Score: 0.076
-
The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
Score: 0.067
-
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
Score: 0.051
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.045
-
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
Score: 0.036
-
Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. 2016 Feb 16; 7(7):7970-8.
Score: 0.016
-
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
Score: 0.015
-
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82.
Score: 0.013
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
Score: 0.012
-
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
Score: 0.009